Search results
Why Shares of Apollomics Are Up Friday
Motley Fool· 11 months agoWhat happened Shares of Apollomics (NASDAQ: APLM) were up more than 11% Friday morning after an analyst initiated coverage on the stock with a buy...
Why Shares of Alvotech Jumped This Week
Motley Fool· 1 year agoWhat happened Shares of Alvotech (NASDAQ: ALVO) were up as much as 28.1% this week, according to data from S&P Global Intelligence. The stock closed last...
Why Shares of Tango Therapeutics Are Dropping Monday
Motley Fool· 7 months agoWhat happened Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37%...
Why Shares of Ambrx Biopharma Fell Tuesday
Motley Fool· 1 year agoWhat happened Shares of Ambrx BioPharma (NYSE: AMAM) fell 28.1% for the day as of late Tuesday afternoon. The clinical-stage biotech announced Monday...
Why Shares of Vaxxinity Soared This Week
Motley Fool· 1 year agoWhat happened Shares of Vaxxinity (NASDAQ: VAXX) were up 36.8% this week as of Thursday's close. The stock closed last week at $1.74. Vaxxinity's shares...
Why Shares of Brookdale Senior Living Tumbled 33.23% on Wednesday
Motley Fool· 1 year agoWhat happened Brookdale Senior Living (NYSE: BKD) saw its shares drop 33.23% on Wednesday. The stock...
Why Shares of Keros Therapeutics Rose 10.2% This Week
Motley Fool· 2 years agoWhat happened Shares of clinical-stage biopharmaceutical company Keros Therapeutics (NASDAQ: KROS)...
Why Intra-Cellular Therapies Climbed Tuesday
Motley Fool· 1 year agoWhat happened Shares of Intra-Cellular Therapeutics (NASDAQ: ITCI) were up 14.8% Tuesday morning after the healthcare company released top-line phase 3...
Why Shares of Legend Biotech Jumped Wednesday
Motley Fool· 1 year agoWhat happened Shares of Legend Biotech (NASDAQ: LEGN) surged by more than 20% on Wednesday morning after a data leak regarding one of its clinical...
2 Green Flags and 1 Red Flag for Novartis Stock
Motley Fool· 7 months agoShare prices of Swiss pharmaceutical company Novartis (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular,...
